Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease

Inclusion Criteria: * Male or female * Age 20-75 years * Diagnosis of type II Diabetes Mellitus for at least 3 months and/or clinical evident cardiovascular disease (CVD) * A hemoglobin A1c concentration has to be \< 8% before screening Exclusion Criteria: * Women of child bearing potential who are pregnant, breastfeeding or not using effective contraceptives * Known hypersensitivity to Pravastatin or any of its components * Have a history of homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia * Significant medical illness * Known serious conditions, e.g. serum creatine kinase(CK)levels 2.5 times upper limit of normal * Subjects being treated with drugs influence serum lipid concentrations * Subjects who have cancer or been receiving the cancer chemotherapy